Skip to main content
. 2024 Sep 7;17(9):1180. doi: 10.3390/ph17091180

Table 8.

Investigational nasal drugs for the treatment of Parkinson’s disease.

API Delivery System Refs.
Celegiline Chitosan nanoparticles [98]
Nanoemulsion [99]
Bromocriptine Chitosan nanoparticles [100]
Rasagiline mesylate Gel in situ [101]
Chitosan glutamate nanoparticles [102]
Chitosan-coated PLGA nanoparticles [103]
Peonol Gel in situ [104]
Dopamine Chitosan nanoparticles [105]
Borneol and lactoferrin co-modified nanoparticles [106]
Pramipexole Chitosan nanoparticles [107]